Ohio State Navbar

Directory

Beth Christian, MD


Staff photo

320 W 10th Avenue
Columbus, OH 43210

Phone: (614) 293-7807

Email: christian.77@osu.edu

 

Current OSU Appointments

Assistant Professor-Clinical, Hematology

Physician, FGP-Hematology

 

Clinical Interest

Malignant Hematology: Lymphoma

Academic Advising

2013 - present Ohio State University College of Medicine.
2014 - present David Bond The Ohio State University.
2010 - 2011 Deborah Stephens The Ohio State University.
2011 - 2012 Kerry Rogers The Ohio State University.
2012 - 2013 Kate Panzer The Ohio State University.
2014 Kevin Koehler The Ohio State University.
2014 - 2015 Wil Santivasi The Ohio State University.
2014 - 2015 Zubin Yavar The Ohio State University.
 

Certifications

present Advanced Cardiac Life Support Certificate: American Heart Association
present Basic Cardiac Life Support Certificate: American Heart Association
2005 - present Board Certification: American Board of Internal Medicine
2009 - present Board Certification: American Board of Internal Medicine
2010 - present Board Certification: American Board of Internal Medicine
2002 - 2005 MD Training Certificate: # 57.005787 (Inactive): State Medical Board of Ohio
2005 - 2017 Doctor of Medicine: License # 35.085172: State Medical Board of Ohio
 

Clinical Services

08/01/2009 Outpatient Hematology Clinic (James Cancer Hospital)
09/01/2009 Hematology Inpatient Service (James Cancer Hospital)

Conferences

Christian BA, Grever M, Byrd JC, Lin TS. "Flavopiridol in Chronic Lymphocytic Leukemia: A Concise Review." In CLINICAL LYMPHOMA & MYELOMA. (September 2009). S179-S185.

Alinari L, Christian B, Yu B, Shin J, Hertlein EK, Lapalombella R, Yan F, Lesinski G, Zhang X, Lozanski G, Muthusamy N, Goldenberg DM, Byrd JC, and Baiocchi RA.. "Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death That Is Dependent On Actin Polymerization and Inhibition of NF-κB." In Blood. (October 2009). Abstract 1694a-.

Jones JA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Deam D, Flynn JM, Johnson JA, Phelps MA, Porcu P, Byrd JC, and Grever MR. "Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma." In BLOOD. (November 2010). 1169-1169.

Racke F, Simpson S, Christian B, Blum KA, Hasserjian R, Zhao W. "Evidence of Long Latency Periods Prior to Development of Mantle Cell Lymphoma.." In BLOOD. (November 2010). 147-147.

Christian B, Alinari L, Earl CT, Wilding E, Quinion C, Lustberg M, Benson DM, Jone JAs, Byrd JC, Wegener,William A, Goldenberg DM, Baiocchi RA, Blum KA. "A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma." In BLOOD. (November 2010). 1148-1149.

Christian B, Alinari L, Jones JA, Benson DM, Flynn JM, Porcu P, Lustberg ME, Phelps M, Poi M, Chung D, Quinion C, Byrd JC, Wegener W, Goldenberg DM, Baiocchi RA, Blum KA. "Results of A Phase 1 Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma." In BLOOD. (November 2011). 1584-1584.

Cohen JB, Geyer S, Lozanski G, Zhao W, Heerema NA, Jones JJ, Porcu P, Christian B, Baiocchi RA, Maddocks K, Flynn JM, Devine SM, Blum KA. "Complete Response (CR) to Induction Therapy in Patients (pts) with Myc plus and Double Hit Non-Hodgkin's Lymphoma (NHL) Is Associated with Prolonged Progression-Free Survival (PFS).." In BLOOD. (November 2012). Abstract 2693-.

Stephens DM, Ruppert AS, Christian BA, Jones JA, Flynn JM, Porcu P, Baiocchi RA, Byrd JC, Dotson EK, Crawford BS, Blum KA.. "Toxicity in patients (pts) age 65 or older with dose-adjusted REPOCH (DA-REPOCH) for untreated diffuse large B-cell lymphoma (DLBCL).." In JOURNAL OF CLINICAL ONCOLOGY. (May 2012). Abstract e18508-.

Hofmeister CC, Liu Z, Bowers MA, Porcu P, Flynn JM, Christian BA, Baiocchi RA, Benson D, Andritsos LA, Greenfield CA, Sell,Megan, Geyer S, Byrd JC, Grever MR. "Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma.." In BLOOD. (November 2012). Abstract #2955-.

Salem G, Dunavin N, Wei L, Elder P, Penza S, Blum K, Porcu P, Baiocchi R, Jones J, Flynn J, Andritsos L, Devine SM, Christian B, Efebera Y. "Busulfan, cyclophosphamide, etoposide is not superior to carmustine, etoposide, cytarabine, mephalan conditioning prior to autologous stem cell transplantation in patients with Hodgkin's lymphoma and is associated with increased toxicity." In BONE MARROW TRANSPLANTATION. (April 2012). S84-S85.

Blum KA, Christian B, Flynn JM, Jaglowski SM, Jones JA, Maddocks K, Byrd JC. "A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)." In BLOOD. (November 2012). Abstract 1643-.

Cohen JB, Ruppert AS, Heerema NA, Jones JA, Porcu P, Baiocchi RA, Christian B, Byrd JC, Flynn JM, Penza S, Andritsos LA, Devine SM, Blum KA.. "Complex Karyotype (CK) Is Associated with a Shortened Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL).." In BLOOD. (November 2012). Abstract 2691-.

Christian B, Kopko A, Fehniger TA, Bartlett NA, Blum KA.. "A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL)." In BLOOD. (November 2012). Abstract 1644-.

Maddocks KJ, Cohen, JB, Christian, BA, Flynn JM, Jaglowski SM, Blum KA. "A Phase II Study of MLN8237 (Alisertib) Alone and in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (NHL)." In BLOOD. (December 2014). .-.

Alinari L, Gru A, Quinion C, Huang Y, Jones JA, Devine SM, Maddocks KJ, Christian, BA, Baiocchi RA, Blum KA. "Poor Prognostic Effect of CD5 Positivity for Patients with Diffuse Large B-Cell Lymphoma: Results from a Retrospective Single Institution Analysis." In BLOOD. (December 2014). .-.

Christian B, Wei L, Sexton J, Jaglowski, SM, Devine SM, Fehniger TA, Wagner-Johnston N, Bartlett NL, Blum KA. "A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL)." In BLOOD. (December 2014). .-.

Christian, B, Kuruvilla J, Smith S, Porcu, P, Ruppert AS, ByrdJC, Grever, MR, Blum KA. "A Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma." In BLOOD. (December 2014). .-.

Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC, Blum KA. "A phase 1/1b study of combined rituximab, bendamustine, and ibrutinib in patients with previously untreated and relapsed/refractory non-Hodgkin's lymphoma." In Blood. (January 2015). 242-248.

 

Degrees

1998 B.S., Tulane University

2002 M.D., The Ohio State University

 

Editorial Activities

2009 - present Clinical Lymphoma and Myeloma
2012 - present Cancer Control: Journal of the Moffitt Cancer Center
2012 - present Current Medical Literature – Leukemia & Lymphoma
2012 - present New England Journal of Medicine
2012 - present Hematology Board Review Manual
2014 - present Leukemia and Lymphoma
2014 - present Blood
2015 - present British Journal of Haematology
 

Honors

2010 - present Outstanding Achievement in Patient Service. The Ohio State University.
2010 - present Faculty Award for Teaching Excellence. The Ohio State University.
2013 - present Faculty Award for Teaching Excellence. The Ohio State University.
 

Journal Articles

Christian BA, Fischer B, Blum KA, Brooker-McEldowney M, Moran ME, Andritsos LA, Phelps MA, Dalton JT, Colevas AD, Byrd JC, Grever MR, Lin TS. "Flavopiridol in Chronic Lymphocytic Leukemia." Clinical Leukemia. Vol. 1, no. 5. (September 2007.): 292-297.

Christian BA, Grever MR, Byrd JC, Lin TS. "Flavopiridol in the Treatment of Chronic Lymphocytic Leukemia (CLL)." Current Opinion In Oncology. Vol. 19, no. 6. (November 2007.): 573-578.

Christian BA, Lin TS. "Antibody Therapy for Chronic Lymphocytic Leukemia (CLL)." Seminars In Hematology. Vol. 45, no. 2. (April 2008.): 95-103.

Christian BA, Grever MR, Byrd JC, Lin TS. "Flavopiridol in Chronic Lymphocytic Leukemia: A Concise Review." CLINICAL LYMPHOMA & MYELOMA. Vol. 9, (September 2009.): S179-S185.

Christian B, Zhao W, Hamadani M, Sotomayor EM, Navarro W, Devine SM, Racke F, Blum KA. "Mantle Cell Lymphoma 12 Years After Allogeneic Bone Marrow Transplantation Occurring Simultaneously in Recipient and Donor." JOURNAL OF CLINICAL ONCOLOGY. Vol. 28, no. 31. (November 2010.): E629-E632.

Alinari L, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, Hertlein E, Lustberg ME, Quinion C, Zhang X, Lozanski G, Muthusamy N, Prætorius-Ibba M, O'Connor OA, Goldenberg DM, Byrd JC, Blum KA, Baiocchi RA. "Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma." BLOOD. Vol. 117, no. 17. (April 2011.): 4530-4541.

Alinari L, Christian B, Baiocchi RA.. "Novel targeted therapies for mantle cell lymphoma." ONCOTARGET. Vol. 3, no. 2. (February 2012.): 203-211.

Cashen AF, Christian BA, Bartlett NL. "Therapy in primary mediastinal B-cell lymphoma.." New England journal of Medicine. Vol. 369, no. 3. (July 2013.): 282-283.

Cohen JB, Hall NC, Ruppert AS, Jones JA, Porcu P, Baiocchi R, Christian BA, Penza S, Benson DM Jr, Flynn J, Andritsos LA, Devine SM, Blum KA.. "Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma." BONE MARROW TRANSPLANTATION. Vol. 48, no. 9. (September 2013.): 1212-1217.

Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JC. "Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma." AMERICAN JOURNAL OF HEMATOLOGY. Vol. 89, no. 1. (January 2014.): 19-24.

Cohen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA, Hall NC, Nagar VA, Hemminger JA, Jones JA, Porcu P, Christian BA, Baiocchi RA, Maddocks KJ, Flynn JM, Devine SM, Blum KA. "Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin’s lymphoma is associated with prolonged progression-free survival.." Cancer. Vol. 120, no. 11. (June 2014.): 1677-1685.

Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC, Blum KA. "A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with previously untreated and relapsed/refractory non-Hodgkin’s lymphoma." Blood. Vol. 125, no. 2. (January 2015.): 242-248.

Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DB, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, and Blum KA. "The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin’s lymphoma." British J of Haematology. Vol. [Epub ahead of print], (April 2015.): .-.

Christian B, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DB, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, and Blum KA. "The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin’s lymphoma." British J of Haematolog. -.

Christian B, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DB, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, and Blum KA.. "The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin’s lymphoma.." British J of Haematology. -.

 

Presentations

"Low Grade Lymphomas." Presented at American Society of Hematology Annual Conference Review, Columbus, OH, US|USA. (January 2010)

"Rituximab: Past, Present, and Future." Presented at Leukemia Lymphoma Society, . (October 2011)

"Lymphoma." Presented at American Society of Hematology (ASH) Annual Review, . (February 2012)

"Clinical Updates in Lymphoma." Presented at American Society of Hematology (ASH) Annual Review, . (January 2015)

 

Professional Activities

present Consulting / Advisory Board. Seattle Genetics, Inc..
present Consulting / Advisory Board. Celgene, Inc..
2015 - present Independent Data Monitoring Committee. GlaxoSmithKline / Novartis.